ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.78
+0.87 (11.00%)
Sep 17, 2026, 11:41 AM EDT - Market open
ImmunityBio Market Cap
ImmunityBio has a market cap or net worth of $9.31 billion as of September 17, 2026. Its market cap has increased by 250.33% in one year.
Market Cap
9.31B
Enterprise Value
10.18B
1-Year Change
250.33%
Ranking
Category
Stock Price
$8.78
ChartMarket Cap Chart
Since March 10, 2021, ImmunityBio's market cap has decreased from $14.82B to $9.31B, a decrease of -37.22%. That is a compound annual growth rate of -8.08%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 17, 2026 | 9.31B | 377.14% |
| Dec 31, 2025 | 1.95B | 4.33% |
| Dec 31, 2024 | 1.87B | -44.23% |
| Dec 29, 2023 | 3.35B | 61.49% |
| Dec 30, 2022 | 2.08B | -14.18% |
| Dec 31, 2021 | 2.42B | -83.68% |
| Mar 10, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Cytokinetics | 9.64B |
| ABIVAX Société Anonyme | 9.44B |
| Kymera Therapeutics | 9.41B |
| Protagonist Therapeutics | 9.28B |
| Vaxcyte | 8.81B |
| Praxis Precision Medicines | 8.74B |
| Twist Bioscience | 8.66B |
| Caris Life Sciences | 8.05B |